Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Relay Therapeutics ( (RLAY) ) has issued an announcement.
Relay Therapeutics announced participation in the 43rd Annual J.P. Morgan Healthcare Conference, highlighting progress in their clinical programs, notably the RLY-2608, aimed at breast cancer. The company anticipates starting pivotal trials and clinical data updates in 2025, supported by a strong financial position and extensive global clinical experience, targeting significant market opportunities in the oncology sector.
More about Relay Therapeutics
Relay Therapeutics is a biotechnology company focusing on developing therapies for cancer and genetic diseases. Utilizing their proprietary Dynamo platform, the company is working on targeted treatments for breast cancer, vascular malformations, and other solid tumors, emphasizing mutant-selective PI3Kα inhibitors.
YTD Price Performance: 3.49%
Average Trading Volume: 2,061,547
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $744.9M
For an in-depth examination of RLAY stock, go to TipRanks’ Stock Analysis page.